Benjamin Holmes, DVM | Authors


Greater Understanding of CLL Pathophysiology Spurs Small Molecules Development

October 25, 2022

William Wierda, MD, PhD, explored the emergence of small molecule-inhibitor targeted therapies during the “Workup of CLL in the Era of Small Molecules,” presentation at the 10th Annual Meeting of the Society of Hematologic Oncology.

Interleukin-Based Treatments Find Footing in Ongoing Research

August 16, 2022

Current- generation cytokines are being engineered to extend their half-life and improve tumor targeting using polyethylene glycol conjugation, fusion to tumor-targeting antibodies, alterations of cytokine/cell receptor–binding affinity, and other strategies.